The Latest Cardiac and Vascular News
Minneapolis, MN, June 26, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics […]
Minneapolis, MN, May 09, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that the Company’s co-authored manuscript with physicians from Mayo Clinic and Harvard Brigham & Women’s Hospital entitled, “Initial […]
Minneapolis, MN, April 26, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced that the Company will be attending the Heart Rhythm Society’s 38th Annual Scientific Sessions May 10-13 at McCormick Place in […]
Ten-year agreement provides know-how, intellectual property development and clinical resources to commercialize the PURE EP System and develop future technologies Minneapolis, MN, March 17, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology […]
